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www.jacc-interventions.org to view.Percutaneous Transcatheter Assessment of the Left Main Coronary Artery:
Current Status and Future Directions1529Rong Bing, Andy S.C. Yong, Harry C. LoweAccurate assessment of the left main coronary artery (LMCA) is critical in determining treatment
strategies and delineating revascularization options to improve prognosis. There has been an
evolution in invasive techniques that allow detailed assessment of both function and anatomy. As
technologies advance, there is an increasing amount of evidence supporting the use of
percutaneous coronary intervention (PCI) for the LMCA. This state-of-the-art paper provides an
in-depth exploration of intravascular ultrasound, fractional ﬂow reserve, and optical coherence
tomography. A discussion is provided that explores the basis for application of these technologies,
the body of evidence for each modality and its use in LMCA assessment, and the potential role in
post-PCI optimization in what is a dynamically changing ﬁeld.CLINICAL RESEARCH
CORONARY A Clinical and Angiographic Scoring System to Predict the Probability of
Successful First-Attempt Percutaneous Coronary Intervention in Patients With
Total Chronic Coronary Occlusion1540Giuseppe Alessandrino, Bernard Chevalier, Thierry Lefèvre, Francesca Sanguineti,
Philippe Garot, Thierry Unterseeh, Thomas Hovasse, Marie-Claude Morice, Yves LouvardTo obtain a scoring model predicting ﬁnal percutaneous coronary intervention for chronic total
occlusion (CTO-PCI) success, the authors analyzed the predictive impact of clinical and angiographic
characteristics of patients who underwent a CTO-PCI. The following independent parameters were
taken into account: previous coronary artery bypass graft surgery, previous myocardial infarction,
severe lesion calciﬁcation, longer CTOs ($20 mm), non–left anterior descending coronary artery
location, and blunt stump morphology. Score values of 0 to 1, >1 and <3, $3 and <5, and $5
identiﬁed subgroups at high, intermediate, low, and very low probability, respectively, of CTO-PCI
success. Increasing score values correlated with low probability of CTO-PCI success.n EDITORIAL COMMENT
Do We Need Another Predictive Scoring Tool for Chronic Total Occlusion
Percutaneous Coronary Intervention?1549R. Michael WymanCONTINUED ON PAGE A-29
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OCTOBER 2015 VOLUME 8, NUMBER 12Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving
Dual Antiplatelet Therapy1552Dean J. Kereiakes, Robert W. Yeh, Joseph M. Massaro, Priscilla Driscoll-Shempp,
Donald E. Cutlip, P. Gabriel Steg, Anthony H. Gershlick, Harald Darius, Ian T. Meredith,
John Ormiston, Jean-François Tanguay, Stephan Windecker, Kirk N. Garratt,
David E. Kandzari, David P. Lee, Daniel I. Simon, Adrian Corneliu Iancu,
Jaroslaw Trebacz, Laura Mauri, on behalf of the DAPT Study InvestigatorsDespite antirestenotic efﬁcacy of coronary drug-eluting stents (DES) compared with bare-metal
stents (BMS), the relative risk of stent thrombosis and adverse cardiovascular events is unclear.
Many clinicians perceive BMS to be associated with fewer adverse ischemic events and to require
shorter duration dual antiplatelet therapy than DES. In a prospective propensity-matched analysis
of 10,026 subjects participating in a randomized trial of dual antiplatelet therapy duration
(DAPT [Dual Antiplatelet Therapy] study), DES-treated subjects had long-term rates of stent
thrombosis that were lower than BMS-treated subjects.
SEE ADDITIONAL CONTENT ONLINEPrasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary
Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt
Thrombosis)1563Renato Valenti, Rossella Marcucci, Vincenzo Comito, Marco Marrani, Giulia Cantini,
Angela Migliorini, Guido Parodi, Gian Franco Gensini, Rosanna Abbate, David AntoniucciThe RECLOSE-3 (REsponsiveness to CLOpidogrel and StEnt thrombosis) study sought to determine
the efﬁcacy of switching to prasugrel in clopidogrel nonresponders. The clinical outcome was
compared with the RECLOSE-2–ACS patient cohort. The 2-year cardiac mortality of the 302
clopidogrel nonresponders who were switched to prasugrel was 4%, whereas it was 9.7% in
nonresponders in the RECLOSE-2–ACS study (p ¼ 0.007). Clopidogrel nonresponsiveness can be
overcome by prasugrel (10 mg/day), and optimal platelet aggregation inhibition with prasugrel
treatment is associated with a low rate of long-term cardiac mortality and stent thrombosis.n EDITORIAL COMMENT
Prasugrel in Clopidogrel Nonresponders: A Way to Improve Secondary Prevention
in Patients After Percutaneous Coronary Intervention?1571Kurt HuberCONTINUED ON PAGE A-30
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OCTOBER 2015 VOLUME 8, NUMBER 12Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary
Percutaneous Coronary Intervention for Acute Coronary Syndromes:
Insights From the National Cardiovascular Data Registry1574David M. Saﬂey, Lakshmi Venkitachalam, Kevin F. Kennedy, David J. CohenNational Cardiovascular Data Registry CathPCI Registry data were used to assess the association
between glycoprotein IIb/IIIa inhibitor (GPI) use and outcomes after percutaneous coronary
intervention for acute coronary syndrome between July 2009 and September 2011. Multiple
statistical methods were used to adjust for potential bias. There were 970,865 patients included;
326,283 (33.6%) received a GPI. Unadjusted mortality and major bleeding were more common
with a GPI. In contrast, GPI use was associated with lower mortality in adjusted analyses; relative
risks ranged from 0.72 (95% conﬁdence interval: 0.50 to 0.97) to 0.90 (95% conﬁdence interval:
0.86 to 0.95). The association of GPI use with bleeding remained in adjusted analyses.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
What Role for Glycoprotein IIb/IIIa Inhibition in Contemporary Coronary Intervention? 1583
A. Michael Lincoff
Drug-Coated Balloons Versus Second-Generation Drug-Eluting Stents for the
Management of Recurrent Multimetal-Layered In-Stent Restenosis1586Hiroyoshi Kawamoto, Neil Ruparelia, Azeem Latib, Tadashi Miyazaki, Katsumasa Sato,
Antonio Mangieri, Rachele Contri, Stefano Stella, Filippo Figini, Alaide Chieffo,
Mauro Carlino, Matteo Montorfano, Antonio ColomboThis study aimed to investigate outcomes between drug-coated balloons (89 lesions) and
second-generation drug-eluting stents (82 lesions) for the treatment of patients with recurrent
drug-eluting stents in-stent restenosis. The rates of major adverse cardiac events were comparable
between groups (14.0% vs. 12.3% at 1 year and 28.8% vs. 43.5% at 2 years, p ¼ 0.21, drug-
eluting stents vs. drug-coated balloons, respectively). Deﬁnite stent thrombosis occurred in
1 patient in each group. Multivariable analysis revealed recurrence of in-stent restenosis within
1 year of the ﬁrst reintervention and lesion length to be independent predictors of future target
lesion revascularization. Larger studies are required to conﬁrm the late differences between groups.CONTINUED ON PAGE A-31
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OCTOBER 2015 VOLUME 8, NUMBER 12STRUCTURAL Acute Kidney Injury With the RenalGuard System in Patients Undergoing
Transcatheter Aortic Valve Replacement: The PROTECT-TAVI Trial
(PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic
intravenous hydraTion in Transcatheter Aortic Valve Implantation)1595Marco Barbanti, Simona Gulino, Piera Capranzano, Sebastiano Immè, Carmelo Sgroi,
Claudia Tamburino, Yohei Ohno, Guilherme F. Attizzani, Martina Patanè, Rita Sicuso,
Gerlando Pilato, Alessio Di Landro, Denise Todaro, Emanuela Di Simone, Andrea Picci,
Giuliana Giannetto, Giuliano Costa, Wanda Deste, Daniela Giannazzo, Carmelo Grasso,
Davide Capodanno, Corrado TamburinoTranscatheter aortic valve replacement (TAVR) is associated with varying degrees of post-procedural
acute kidney injury (AKI). The RenalGuard System (PLC Medical Systems, Milford, Massachusetts) is a
dedicated device designed for contrast-induced AKI prevention. Whether this device is also effective
in patients with severe aortic stenosis undergoing TAVR is unexplored. The results of this single-
center randomized study powered to detect differences in AKI within 72 h after TAVR demonstrate
that a prophylactic intravenous loading dose of 250-ml normal saline solution combined with
furosemide-induced high-volume diuresis and maintenance of intravascular volume through
automatic matched hydration (RenalGuard system) is safe and superior to standard infusion of
normal saline solution at a high dose.n EDITORIAL COMMENT
Prevention of Acute Kidney Injury With the RenalGuard System in Patients
Undergoing Transcatheter Aortic Valve Replacement: The PROTECT-TAVI Trial
(PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic
intravenous hydraTion in Transcatheter Aortic Valve Implantation)1605Charanjit S. Rihal, Kianoush B. Kashani
Increased Risk of Cerebral Embolization After Implantation of a Balloon-Expandable
Aortic Valve Without Prior Balloon Valvuloplasty1608Klaudija Bijuklic, Timo Haselbach, Julian Witt, Korff Krause, Lorenz Hansen,
Ralf Gehrckens, Friedrich-Christian Rieß, Joachim SchoferTranscatheter aortic valve replacement (TAVR) without prior balloon valvuloplasty is increasingly
used to simplify the procedure; however, the risk of cerebral embolization is unknown. The
authors analyzed cerebral ischemic lesions in diffusion-weighted magnetic resonance imaging after
TAVR with prior balloon valvuloplasty (BAV) compared with TAVR without prior BAV using a
balloon-expandable aortic valve. TAVR without BAV was associated with a signiﬁcantly shorter
procedural time and lower contrast volume, but patients with BAV had a signiﬁcantly higher total
volume of cerebral ischemic lesions.CONTINUED ON PAGE A-32
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OCTOBER 2015 VOLUME 8, NUMBER 12PERIPHERAL Paclitaxel-Coated Balloon in Infrapopliteal Arteries:
12-Month Results From the BIOLUX P-II Randomized Trial
(BIOTRONIK’S–First in Man study of the Passeo-18 LUX drug releasing PTA
Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects
requiring revascularization of infrapopliteal arteries)1614Thomas Zeller, Ulrich Beschorner, Ernst Pilger, Marc Bosiers, Koen Deloose,
Patrick Peeters, Dierk Scheinert, Karl-Ludwig Schulte, Aljoscha Rastan,
Marianne BrodmannIn the BIOLUX P-II (BIOTRONIK’S–First in Man study of the Passeo-18 LUX drug releasing PTA Balloon
Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of
infrapopliteal arteries) randomized controlled trial, the safety and efﬁcacy of a novel paclitaxel-
coated drug-eluting balloon (DEB) versus an uncoated balloon (percutaneous transluminal
angioplasty [PTA]) was assessed in 72 patients with infrapopliteal lesions. The composite of all-
cause mortality, target extremity major amputation, target lesion thrombosis, and target vessel
revascularization at 30 days was 0% in the DEB versus 8.3% in the PTA group, and primary
patency at 6 months was 17.1% versus 26.1%, respectively. In conclusion, the Passeo-18
Lux (Biotronik, Berlin, Germany) has been proven to be safe and effective with comparable
outcomes to PTA.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Missing the Forest for the Trees? Drug-Eluting Balloon Treatment for
Infrapopliteal Disease1623Thomas T. Tsai
Fate of Hypoplastic Pulmonary Arteries After Arterial Duct Stenting in
Congenital Heart Disease With Duct-Dependent Pulmonary Circulation1626Giuseppe Santoro, Gianpiero Gaio, Giovanbattista Capozzi, Luca Giugno,
Maria Teresa Palladino, Cristina Capogrosso, Angelo Fabio D’Aiello, Giuseppe Caianiello,
Maria Giovanna RussoPulmonary artery (PA) growth was evaluated in 45 newborns submitted to arterial duct (AD) stenting
as palliation of congenital heart disease with duct-dependent pulmonary circulation according to
the original vessel size (hypoplastic PAs, Group I [n ¼ 15]; mildly reductive PAs, Group II [n ¼ 30]).
At follow-up angiography, the Nakata Index signiﬁcantly increased in the whole population
(124  118%, p < 0.0001). Percentage growth was signiﬁcantly higher in Group I (227  141% vs.
72  57%, p < 0.0001), resulting in a ﬁnal PA size not signiﬁcantly different between groups
(246  105 mm2/m2 vs. 282  78 mm2/m2, p ¼ NS). AD stenting is effective in promoting
balanced growth of diminutive PAs as a reliable alternative to surgical palliation.CONTINUED ON PAGE A-33
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INTERVENTIONHybrid Therapy Consisting of Balloon Maceration and Subsequent Fogarty
Thrombectomy for Subacute Lower Limb Ischemia1633Masahiro Yamamoto, Osami Kawarada, Shingo Sakamoto, Koichiro Harada,
Teruo Noguchi, Satoshi Yasuda, Hisao Ogawa
Positive Vessel Remodeling and Appearance of Pulsatile Wall Motion at Long-Term
Follow-Up After Bioresorbable Scaffold Implantation in a Chronic Total Occlusion1635Akihito Tanaka, Neil Ruparelia, Hiroyoshi Kawamoto, Azeem Latib, Antonio Colombo
n ONLINE FEATURE Right Ventricular Free Wall Hematoma: Contemporary
Multimodal Imaginge195M. Fuad Jan, Suhail Allaqaband, Khawaja Afzal Ammar, Sara Fetke, A. Jamil Tajik
n ONLINE FEATURE Accidental Extraction of a Stent Implanted 3 Years Earlier
by a Dislodged Stent: A Rare Complication of Percutaneous Coronary Interventione197Qing Qin, Jianying Ma, Chenguang Li, Lei Ge, Juying Qian, Junbo Ge
n ONLINE FEATURE Severe Generalized Resistant Spasm of the Right Coronary
Artery Causing Hemodynamic Collapse After Stentinge199Ajit Bhagwat, Sachin Mukhedkar
n ONLINE FEATURE “Protruding Myocardium” as a Target for Percutaneous
Transluminal Septal Myocardial Ablation in a Case of Hypertrophic Obstructive
Cardiomyopathye201Yuichiro Maekawa, Keitaro Akita, Hikaru Tsuruta, Fumiaki Yashima, Mai Kimura,
Yoshitake Yamada, Takashi Kawakami, Hideaki Kanazawa, Kentaro Hayashida,
Shinsuke Yuasa, Mitsushige Murata, Masahiro Jinzaki, Keiichi Fukuda
n ONLINE FEATURE Surgical Ligation of Bilateral Large Coronary Artery Fistula
to Pulmonary Arterye203Po-Chi Liao, Shih-Rong Hsieh, Yu-Cheng Hsieh, Si-Wa Chan, Kuo-Yang Wang,
Yen Chang, Wei-Wen Lin
n ONLINE FEATURE Impact of the Orbital Atherectomy System on a Peripheral
Calciﬁed Lesion: Quantitative Analysis by Intravascular Echogenicitye205Yohei Sotomi, Nicolas W. Shammas, Pannipa Suwannasom, Carlos M. Campos,
Joanna J. Wykrzykowska, Robbert J. de Winter, Jouke Dijkstra, Patrick W. Serruys,
Yoshinobu Onuma
n ONLINE FEATURE THESE ARTICLES DO NOT APPEAR IN THE PRINTED ISSUE.
THEY ARE AVAILABLE IN THE ONLINE VERSION OF THIS ISSUE.CONTINUED ON PAGE A-34
CONTENTS
PAGE A-34
OCTOBER 2015 VOLUME 8, NUMBER 12LETTERS TO
THE EDITORSympathetic and Autonomic Effects of Renal Denervation on Atrial Remodeling
and Atrial Arrhythmias1638Salvatore Patanè
Reply
Stephan H. Schirmer, Dominik Linz, Felix Mahfoud, Michael Böhm
Post-Percutaneous Coronary Intervention Angina: A New Performance Measure? 1639
Rosanna Tavella, Isuru Ranasinghe, Chris Zeitz, John F. Beltrame
Reply
Clemens von Birgelen, Liefke C. van der Heijden, Hanim Sen, Marije M. Löwik
Endovascular Bariatrics: First in Humans Study of Gastric Artery Embolization
for Weight Loss1641Nickolas Kipshidze, Akaki Archvadze, Stefan Bertog, Martin B. Leon, Horst SievertEDITOR’S PAGE How Did Andreas Get Here? 1645
Spencer B. King III
